A method of detecting the presence of fentanyl or a fentanyl analogue in a sample which comprises contacting the sample with a 1,2 naphthoquinone (such as 1,2-naphthoquinone itself) in a solvent, preferably acetonitrile, and observing a colour change, which when present, correlates with the presence of fentanyl or a fentanyl analogue. Optionally, a buffer may be provided to maintain an alkaline environment and/or a metal halide catalyst and/or light source may be added to accelerate colour development.

The present invention relates to detection systems for detecting an opioid compound by use of pyrolysis, as well as methods thereof. In particular, the systems are configured to detect the presence of a backbone fragment indicative of a class of opioid compounds, including opioid analogues.

Provided are devices, kits, and methods for rapid detection of analytes of interest, such as drugs of abuse, at comparatively low concentrations. The technology includes competitive assay lateral flow devices that utilize a nanoparticle-antibody complex to provide a visually-perceptible marker upon contact with a sample having above a cutoff level of analyte.

The present invention provides an apparatus for detecting the presence or absence of an analyte in liquid sample, including: a collection chamber, including an opening for collecting a liquid sample; a testing element for testing the analyte in liquid sample; and a cover for covering the opening of the collection chamber; wherein the apparatus further includes a prompting device for prompting if the cover is covered to a specified location, and the prompting device shall at least includes a first element and a second element, the first element is in contact with the second element, wherein one element vibrates to produce a sound. In some preferred ways, the second element produces friction with the first element, to cause one of the elements to generate vibrations. The apparatus in the present invention can allow the prompting sound to be clear and loud.

The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.

The present invention discloses a detection apparatus, comprising a base layer, wherein the base layer comprises a groove for containing a testing element and a sample chamber for collecting a fluid sample. The detection apparatus can achieve fast, efficient and accurate detection of analytes in liquid samples, make operators to perform testing conveniently and freely, without causing incorrect results. In some preferred modes, the sample chamber comprises a liquid channel.

The present invention includes a method for identifying a patient response to treatment for Alzheimer's Disease with a non-steroidal anti-inflammatory drug (NSAID) or an acetylcholinesterase (AChE) inhibitor drug comprising: obtaining a blood or serum sample from the patient; determining the presence of a proinflammatory endophenotype in the blood or serum sample of the patient; using the proinflammatory endophenotype to detect treatment response (a responder, a stable, a non-responder or an adverse responder); and treating the patient with the NSAID or the AChE inhibitor if the patient is in the responder or the stable treatment response phenotype group; or preventing a treatment with the NSAID or the AChE inhibitor if the patient is a non-responder or an adverse responder.

A safe and reliable drug detection device is provided that detects the presence of opioids and other amine-containing drugs, and enables first responders, law enforcement personnel, and others to avoid inadvertent exposure to these potentially lethal drugs. The detector device includes a substrate and a dye that produces a visible color change rapidly when the device is brought into contact with an opioid or other amine-containing drug. A method for preparing the detector device and a method for detecting opioids and other amine-containing drugs on a surface are also provided.

Methods, compositions and kits for quantitatively determining specified amounts of 11dhTxB2 in microliter to milliliter quantities of a given sample, wherein, the sample is a biological fluid. Specifically, the biological fluid is a quantity of 1 ml or less of urine from a human subject. The methods may be in the form of consolidated assays that can be run in a high throughput, automation format, such as an enzyme-linked immunosorbent assay (ELISA). Further, the ELISA may be modified into a chemiluminescence assay in order to increase sensitivity and linear range and to reduce the reaction time.

An exemplary breath analysis system may include a sampling chamber having a molecule collector disposed therein. The molecule collector may be configured such that volatile organic compounds (VOCs) present in a breath sample introduced to the sampling chamber adhere to the molecule collector. A heating element may introduce heat within the sampling chamber, causing release of at least a portion of the VOCs adhered to the molecule collector. An analysis device (e.g., a mass spectrometer or Terahertz (THz) spectrometer) may identify one or more target VOCs from among at least the portion of the VOCs released from the molecule collector and generate an output representative of the identified one or more target VOCs. The output may include information that quantitates a concentration of the one or more target VOCs with respect to a source of the breath sample.